v3.25.2
Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at Dec. 31, 2023 $ 649 $ 228,203,706 $ 22,243 $ (225,704,176) $ 2,522,422
Balance (in shares) at Dec. 31, 2023 648,761        
Issuance of common stock in reverse stock split $ 115 (115)      
Issuance of common stock in reverse stock split (in shares) 114,735        
Issuance of common stock in public offering $ 205 4,741,195     4,741,400
Issuance of common stock in public offering (in shares) 204,694        
Issuance costs associated with sales of common stock   (625,065)     (625,065)
Issuance of common stock associated with conversion of debt $ 36 254,220     254,256
Issuance of common stock associated with conversion of debt (in shares) 36,790        
Issuance of common stock upon exercise of pre-funded warrants $ 537 8,063     8,600
Issuance of common stock upon exercise of pre-funded warrants (in shares) 537,500        
Share-based compensation expense   117,636     117,636
Foreign currency translation adjustment     5,356   5,356
Net loss       (3,559,829) (3,559,829)
Balance at Jun. 30, 2024 $ 1,542 232,699,640 27,599 (229,264,005) 3,464,776
Balance (in shares) at Jun. 30, 2024 1,542,480        
Balance at Mar. 31, 2024 $ 658 228,363,074 24,143 (227,619,503) 768,372
Balance (in shares) at Mar. 31, 2024 657,900        
Issuance of common stock in reverse stock split $ 115 (115)      
Issuance of common stock in reverse stock split (in shares) 114,735        
Issuance of common stock in public offering $ 205 4,741,195     4,741,400
Issuance of common stock in public offering (in shares) 204,694        
Issuance costs associated with sales of common stock   (625,065)     (625,065)
Issuance of common stock associated with conversion of debt $ 27 154,813     154,840
Issuance of common stock associated with conversion of debt (in shares) 27,651        
Issuance of common stock upon exercise of pre-funded warrants $ 537 8,063     8,600
Issuance of common stock upon exercise of pre-funded warrants (in shares) 537,500        
Share-based compensation expense   57,675     57,675
Foreign currency translation adjustment     3,456   3,456
Net loss       (1,644,502) (1,644,502)
Balance at Jun. 30, 2024 $ 1,542 232,699,640 27,599 (229,264,005) 3,464,776
Balance (in shares) at Jun. 30, 2024 1,542,480        
Balance at Dec. 31, 2024 $ 2,514 238,040,520 45,789 (233,970,752) $ 4,118,071
Balance (in shares) at Dec. 31, 2024 2,514,499       2,514,499
Issuance of common stock pursuant to At Market Issuance Sales Agreement $ 979 3,242,198     $ 3,243,177
Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares) 978,105        
Issuance costs associated with sales of common stock   (72,165)     (72,165)
Issuance of common stock to vendors $ 12 29,988     30,000
Issuance of common stock to vendors (in shares) 12,346        
Share-based compensation expense   163,112     163,112
Net loss       (5,653,244) (5,653,244)
Balance at Jun. 30, 2025 $ 3,505 241,403,653 45,789 (239,623,996) $ 1,828,951
Balance (in shares) at Jun. 30, 2025 3,504,950       3,504,950
Balance at Mar. 31, 2025 $ 3,183 240,770,981 45,789 (236,922,020) $ 3,897,933
Balance (in shares) at Mar. 31, 2025 3,183,992        
Issuance of common stock pursuant to At Market Issuance Sales Agreement $ 322 545,313     545,635
Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares) 320,958        
Issuance costs associated with sales of common stock   (12,154)     (12,154)
Share-based compensation expense   99,513     99,513
Net loss       (2,701,976) (2,701,976)
Balance at Jun. 30, 2025 $ 3,505 $ 241,403,653 $ 45,789 $ (239,623,996) $ 1,828,951
Balance (in shares) at Jun. 30, 2025 3,504,950       3,504,950